Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XR0B
|
|||
| Former ID |
DNCL003770
|
|||
| Drug Name |
SPI-205
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 2 | [1] | |
| Company |
SPECTRUM pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Low-affinity nerve growth factor receptor (NGFR) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Neurotrophin signaling pathway | ||||
| Transcriptional misregulation in cancer | ||||
| Pathway Interaction Database | p75(NTR)-mediated signaling | |||
| Neurotrophic factor-mediated Trk receptor signaling | ||||
| Reactome | Axonal growth inhibition (RHOA activation) | |||
| NRAGE signals death through JNK | ||||
| p75NTR negatively regulates cell cycle via SC1 | ||||
| Regulated proteolysis of p75NTR | ||||
| NADE modulates death signalling | ||||
| NRIF signals cell death from the nucleus | ||||
| p75NTR recruits signalling complexes | ||||
| NF-kB is activated and signals survival | ||||
| Axonal growth stimulation | ||||
| WikiPathways | Spinal Cord Injury | |||
| BDNF signaling pathway | ||||
| Signalling by NGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00041795) Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy. U.S. National Institutes of Health. | |||
| REF 2 | AIT-082 NeoTherapeutics Inc. IDrugs. 1998 Oct;1(6):694-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.